Alzheimer Disease Clinical Trials in Tampa, Florida

10 studies are recruiting for alzheimer disease in Tampa, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

   The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who c…

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   IPTB Clinical Research, Tampa, Florida

   Locations

   252 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06937229 on ClinicalTrials.gov

2. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

   This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

   Stage

   Phase 2

   Ages

   55 to 90

   Site

   Local Institution - 0001, Tampa, Florida

   Locations

   78 in total

   Run by

   Celgene

   See if you can join NCT06808984 on ClinicalTrials.gov

3. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

   This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.

   Stage

   Phase 2

   Ages

   55 and older

   Site

   University of South Florida, Tampa, Florida

   Locations

   67 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06540833 on ClinicalTrials.gov

4. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

   The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Guardian Angel Research, Tampa, Florida

   Locations

   293 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT06585787 on ClinicalTrials.gov

5. AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

   This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation study evaluating the safety, tolerability, and immunogenicity of AV-1980R, an investigational vaccine targeting pathological tau, in participants with preclinical Alzheimer's disease. Up to 48 cog…

   Stage

   Phase 1

   Ages

   65 to 80

   Site

   University of South Florida, Tampa, Florida

   Locations

   6 in total

   Run by

   Institute for Molecular Medicine

   See if you can join NCT07158905 on ClinicalTrials.gov

6. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

   The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

   Stage

   Phase 3

   Ages

   55 and older

   Site

   Care Access - Tampa, Tampa, Florida

   Locations

   59 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07602582 on ClinicalTrials.gov

7. A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

   The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). …

   Stage

   Phase 1

   Ages

   45 to 85

   Site

   K2 Medical Research - Tampa, Tampa, Florida

   Locations

   13 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06657768 on ClinicalTrials.gov

8. Clinical Trial on Agitation in Alzheimer's Dementia

   The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.

   Stage

   Phase 2

   Ages

   60 and older

   Site

   University of South Florida Department of Psychiatry and Behavioral Neurosciences, Tampa, Florida

   Locations

   31 in total

   Run by

   IGC Pharma, LLC

   See if you can join NCT05543681 on ClinicalTrials.gov

9. Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP)

   The palliative care education in assisted living for dementia care providers (PCEAL-DCP) is a 4-week intervention (once a week for 1.5 hours, a total of 6 hours) for licensed nurses, administrators and dementia care coordinators to improve quality of dementia care outcomes

   Stage

   Not phased

   Ages

   21 and older

   Site

   University of South Florida, Tampa, Florida

   Locations

   2 in total

   Run by

   University of South Florida

   See if you can join NCT06722352 on ClinicalTrials.gov

10. ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

    The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

    Stage

    Not phased

    Ages

    50 to 85

    Site

    Tampa General Hospital, Tampa, Florida

    Locations

    10 in total

    Run by

    InSightec

    See if you can join NCT03671889 on ClinicalTrials.gov